Dr. Ali Harandi has a long-standing interest and experience in mucosal immunity and adjuvants with special emphasis on vaccine and adjuvant development to counter genital herpes. Dr. Harandi and his colleagues recently developed the novel potent adjuvant CTB-CpG with combined properties of TLR9 agonist and CTB. Dr. Harandi has coordinated several collaborative research projects on mucosal adjuvants and vaccines against genital herpes, involving the Karolinska Institute, Lund University, Linköpings University, WHO collaborating Institute of Primate Research in Nairobi, a Plant-based vaccine Center in Giza Egypt and Finlay Institute in Cuba, and is currently involved in a FP7 funded project on multivalent nanoparticle-based vaccines for HIV and genital herpes.
Dr. Harandi has been serving as expert, advisor and member to a number of national and European committees including the European Commission (EC)-DG Research Health, European Developing Countries Clinical Trial Partnership (EDCTP) as well as advisor to several EC funded consortia and European biotech companies. Dr. Harandi has organized several international workshops and symposia on vaccines and adjuvants and has given several keynote and invited talks in international meetings and conferences.